Navigation Links
IFRS Information - First Half of 2007
Date:9/13/2007

rge of $1.8 million for share based compensation under IFRS 2, Share Based Payments, (2006: $1.5 million).

Research and development (R&D)

R&D expenditure increased from $150.0 million in the six months to June 30, 2006 to $277.1 million in the six months to June 30, 2007.

The increase in R&D expenditure during the six months to June 2007 primarily results from a non-cash charge of $100.0 million recognized on the effective settlement of Shire's pre-existing relationship with New River. This charge represents the write-off of capitalized up-front and milestone payments made by Shire prior to the acquisition of New River. This charge is presented within R&D as at the time of the New River acquisition VYVANSE, although approved by the FDA, had not yet received the final scheduling classification from the Drug Enforcement Agency ("DEA") and was therefore not available for commercial sale. Further details in respect of this charge are included in Note 3 to these IFRS interim financial statements.

Excluding this charge of $100 million on the effective settlement of the pre-existing relationship with New River, R&D expenditure in the six months to June 30, 2007 was $177.1 million, (2006: $150.0 million), an increase of $27.1 million, (18%). In 2007, R&D expenditure includes costs associated with Phase 3(b) and Phase 4 studies to support new product launches and the continuation of Phase 3 trials on GA-GCB, the development of the Women's Health and the New River franchises, pre-clinical development of three HGT projects, two new Phase 1 projects and two further pre-clinical projects.

For the six months to June 30, 2007 R&D expenditure included a charge of $5.4 million (2006: $2.8 million) in respect of share based compensation.

Selling, general and administrative (SG&A) expenses

SG&A expenses increased from $435.2 million in the six months to June 30, 2006 to $633.6 million in the six months to June 30, 2007, an increase of 46%. As
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Imaging and Analysis of DIGE Product Information Sheet, Rev B
2. Study affirms information technology-productivity link
3. TrafficCast integrates new information source
4. Rote education fails the Information Age
5. Weather information companies launch data product
6. TeraMedica launches information manager
7. Global information firm reaches diverse markets
8. Preparing for avian flu with information technology
9. Businesses cant hide personal information losses, theft
10. S.C. Johnson lands in No. 2 spot in Information Week 500 list
11. Crate and Barrel deploys Firstlogics Information Quality Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... Achim Noack has been named global ... In this position, Noack will assist Jerry Stoller, CEO ... marketing strategy and supervise global marketing management and implementation ... tremendous knowledge and experience in the crop protection industry,” ... and innovative thinking will be a great asset for ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... 17, 2014  United Therapeutics Corporation (NASDAQ: ... well as changes to Martine Rothblatt , Ph.D,s ... United Therapeutics announced the promotion of ... Officer and David Zaccardelli , Pharm.D. to Executive ... these promotions, Dr. Rothblatt,s title will change from Chairman ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4
... File Supplemental New Drug Application in the Fourth ... ... (Nasdaq:,CEPH) today announced positive results from a 12-week, Phase 3 clinical,trial of ... broad range of chronic non-cancer pain,conditions. The study achieved statistical significance on ...
... DIEGO and AUSTIN, Texas, Aug. 16 DJO Incorporated,(NYSE: ... services that promote,musculoskeletal and vascular health, today reported that ... granted early termination of the,waiting period under the Hart-Scott-Rodino ... acquisition of DJO by an affiliate of,ReAble Therapeutics, Inc. ...
... Ardea Biosciences Receives Milestone Payment from Valeant Pharmaceuticals ... ... CARLSBAD, Calif., Aug. 16 Ardea Biosciences,Inc. (Pink Sheets: ARDC) today ... from its collaboration partner, Valeant,Pharmaceuticals International (NYSE: VRX ). ...
Cached Biology Technology:Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 2DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 3DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 4Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc. 2
(Date:11/21/2014)... , November 18, 2014 ... Systems Market by Systems (Video, RFID, Access Control, Intrusion ... Factories, Hotels, Banks, Government), Component Service Geography - Global ... Systems Market is projected to be around $25 Billion ... by 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... a new ultra-small species of bacteria that has survived ... a Greenland glacier at a depth of nearly two ... low-temperature, high-pressure, reduced-oxygen, and nutrient-poor habitat makes it particularly ... in a variety of extreme environments on Earth and ...
... often turns out there is more to commonplace everyday ... or fall of water droplets from a tap, are ... of singularities requiring sophisticated mathematical techniques to describe, analyse ... in common between many such singular events across the ...
... SPRING HARBOR, N.Y. (Monday, June 2, 2008) With ... that the number of copies of a genes and other ... number variation (or CNV), contributes to our species, genetic diversity ... month,s issue of Cold Spring Harbor Protocols ( ...
Cached Biology News:A survivor in Greenland: A novel bacterial species is found trapped in 120,000-year-old ice 2Finding out what the Big Bang and ink jets have in common 2Finding out what the Big Bang and ink jets have in common 3Cold Spring Harbor Protocols features methods for analyzing genomes and plant cells 2
... trap mass spectrometer enables high-throughput solutions for ... linear ion trap mass spectrometer is designed ... the fast cycle time and increased sensitivity ... an attractive price. The combination of ...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... long and short-term enriched housing for nonhuman ... quarantine and non-quarantine settings on a per ... utilizing our state-of-the-art social housing and nursery ... on site CDC quarantine facilities. Primate ...
... These are just some the things youll be ... Protein-Protein Interactions, edited by Erica Golemis, One look ... edited compilation of topics in protein interaction will ... that must be a part of your personal ...
Biology Products: